also be found in other large reports [3]. The extremely low rate of 10%, as mentioned by Numata, is more likely an extraordinary exception.
I read with interest the article by Drews et al. [1] about the use of transcatheter aortic valve implantation (TAVI) after homograft valve surgery. Surprisingly, I realized that both the authors and the manufacturing company are not aware that the TAVI valve was already implanted in the case of homograft degeneration [2] .
Aortic valve replacement in patients with a previous homograft implantation remains a technical challenge, above all in extremely calcified aortic roots. The traditional surgical approach has a perioperatively reported surgery mortality of between 3 and 8%.
TAVI represents a valid alternative in the case of homograft valve reintervention.
Considering the homograft insertion technique, it could be useful to slowly deploy the balloon valve twice, thus permitting the gentle displacement of the valve [2, 3] .
TAVI represents a very interesting option compared with the traditional surgival approach in patients with valve redo and is a safe and successful alternative.
